Replies to post #261205 on Avid Bioservices Inc (CDMO)

[jq1234]

Look at the numbers:

SNY/REGN Aflibercept and Docetaxel Versus Docetaxel Alone, trial design: mOS=9.5 vs 7.5 months, HR=0.78; result: mOS=10.1 vs 10.4 months, HR=1.01.

Aflibercept performed slightly better than expected, 10.1 months vs 9.5 months, but docetaxel is performing dramatically better than expected, 10.4 months vs 7.5 months. Sound familiar? If SNY/REGN were a small biotech company, PR would be like this:

Aflibercept combination group is performing as expected according to the original trial assumptions in terms of overall survival, while the docetaxel group is dramatically outperforming overall survival expectations based on the original trial assumption and as compared to recently published studies.

SNY/REGN instead gave you a standard drug failed PR: addition of Aflibercept to docetaxel didn't improve overall survival over docetaxel which is all that matters. Read PR by its true content, not by rationalization. Or watch what they do, not what they say: stop other chemo trials!

[north40000]

Interesting, nh. The unusual control arm results in REGN/SNY appear contemporary with PPHM's, not well in the past; hence not clear and convincing evidence that PPHM should have been able to predict from past control arm results.